Newsroom

Press Releases

See All

03/01/2021

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
02/27/2021

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/25/2021

Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45

News Features

01/13/2021

How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
12/18/2020

Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
10/14/2020

Welcome to GT‐FAQ!
09/29/2020

Expanding Access to Newborn Screening for Those with Rare Diseases
09/14/2020

Room to Grow – From Sarepta Intern to Making Impact on the Pipeline
06/12/2020

Patiently Waiting

Media Library

View All Media Library

Sarepta Corporate Logo

Sarepta Building Exterior thumbnail

Sarepta Building Exterior

LGMD Fact sheet thumbnail

LGMD Fact Sheet

Press Contact

Tracy Sorrentino
Senior Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052